CD274 and non-small cell lung carcinoma: The long-term follow-up analysis of Keynote 024 showed that more than 30% of patients with advanced NSCLC with a PD-L1 tumor proportional score (TPS) ≥ 50% who received initial treatment with pembrolizumab achieved a 5-year survival.